Associations among serum levels of MMP-1, MMP-2, and METAVIR fibrosis score in patients with nonalcoholic fatty liver disease Serum MMP-1, MMP-2 in liver fibrosis
Gastroenterology and Hepatology from Bed to Bench,
Vol. 18 No. 3 (2025),
26 August 2025
https://doi.org/10.22037/ghfbb.v18i3.3168
Abstract
Aim: We evaluated their diagnostic potential compared to histopathology and standard biochemical tests of liver function.
Background: Liver fibrosis is considered a reversible condition, making early diagnosis essential. Serum levels of matrix metalloproteinase (MMP) -1 and MMP-2 are investigated as parameters for diagnosing fibrosis in chronic liver disease.
Methods: Commercially available ELISA assays were used to study serum levels of MMP-1 and MMP-2 in 50 patients with nonalcoholic fatty liver disease (NAFLD). Fibrosis stages were evaluated using the METAVIR scoring system. Spearman’s coefficient analysed correlations of serum levels of MMP-1, MMP-2, and liver biopsy score, and specificity and sensitivity were calculated through receiver operating characteristic (ROC) analysis.
Results: MMP-1 levels in fibrosis stage F1 (14.20±3.10 ng/mL) were not significantly different from stage F2 (9.26±2.21 ng/mL) but were higher (p<0.001) than F3 (7.15±1.56 ng/mL) and F4 (4.53±0.62 ng/mL). MMP-2 levels in F1 (68.57±8.22 ng/mL) were similar to F2 (76.31±9.25 ng/mL) but lower (p<0.001) than F3 (103.34±17.59 ng/mL) and F4 (214.24±46.72 ng/mL). Significant differences were seen between mild fibrosis (F1-2) and severe fibrosis/cirrhosis (F3-4) for MMP-1 (p<0.01) and MMP-2 (p<0.001). Correlation analysis revealed a weak inverse correlation for MMP-1 (r=-0.383, p<0.01) and a weak direct correlation for MMP-2 (r=0.392, p<0.01) with fibrosis stages. MMP-2 levels >86.78 ng/mL had a sensitivity of 73.7% and specificity of 61.3% for fibrosis detection, while MMP-1 levels <4.96 ng/mL had a sensitivity of 52.6% and specificity of 32.3%. Using ROC analysis, MMP-2 had significant diagnostic ability in detecting liver fibrosis stages (area under the curve 0.722, p<0.01).
Conclusion: Serum levels of MMP-2 are able to detect liver fibrosis. Despite the limited sample size, these findings support further investigation and potential integration of MMP-2 testing into routine clinical practice.
- liver fibrosis
- serum bio-marker
- matrix metalloproteinases
- noninvasive
- MMP-2
- MMP-1
How to Cite
References
Khan S, Saxena R. Regression of Hepatic Fibrosis and Evolution of Cirrhosis: A Concise Review. Adv Anat Pathol 2021;28:408–414.
Lee MJ. A review of liver fibrosis and cirrhosis regression. J Pathol Transl Med 2023;57:189–195.
Anstee QM, Castera L, Loomba R. Impact of non-invasive biomarkers on hepatology practice: Past, present and future. J Hepatol 2022;76:1362–1378.
Reinson T, Buchanan RM, Byrne CD. Noninvasive serum biomarkers for liver fibrosis in NAFLD: current and future. Clin Mol Hepatol 2023;29:157–170.
Parola M, Pinzani M. Liver fibrosis in NAFLD/NASH: from pathophysiology towards diagnostic and therapeutic strategies. Mol Aspects Med 2024;95:101231.
Bedossa P, Paradis V. Liver extracellular matrix in health and disease. J Pathol 2003;200:504–515.
Martinez-Hernandez A, Amenta PS. The hepatic extracellular matrix. I. Components and distribution in the normal liver. Virchows Arch A Pathol Anat Histopathol 1993;423:1–11.
Calabro SR, Maczurek AE, Morgan AJ, Tu T, Wen VW, Yee C, et al. Hepatocyte produced matrix metalloproteinases are regulated by CD147 in liver fibrogenesis. PLoS One 2014;9:e90571.
Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010;141:52–67.
Roderfeld M. Matrix metalloproteinase functions in hepatic injury and fibrosis. Matrix Biol 2018;68-69:452–462.
Parks WC, Wilson CL, López-Boado YS. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol 2004;4:617–629.
Nissinen L, Kähäri VM. Matrix metalloproteinases in inflammation. Biochim Biophys Acta 2014;1840:2571–2580.
Bourboulia D, Stetler-Stevenson WG. Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): Positive and negative regulators in tumor cell adhesion. Semin Cancer Biol 2010;20:161–168.
Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003;92:827–839.
Geervliet E, Bansal R. Matrix Metalloproteinases as potential biomarkers and therapeutic targets in liver diseases. Cells 2020;9.
Yilmaz Y, Eren F. Serum biomarkers of fibrosis and extracellular matrix remodeling in patients with nonalcoholic fatty liver disease: association with liver histology. Eur J Gastroenterol Hepatol 2019;31:43–46.
Mitropoulou G, Kompoura V, Saffioti F, Mavroeidis VK. The role of matrix metalloproteinases in liver function and disease. Front Biosci 2025;30:27127.
Ando W, Yokomori H, Tsutsui N, Yamanouchi E, Suzuki Y, Oda M, et al. Serum matrix metalloproteinase-1 level represents disease activity as opposed to fibrosis in patients with histologically proven nonalcoholic steatohepatitis. Clin Mol Hepatol 2018;24:61–76.
Kasahara A, Hayashi N, Mochizuki K, Oshita M, Katayama K, Kato M, et al. Circulating matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as serum markers of fibrosis in patients with chronic hepatitis C. Relationship to interferon response. J Hepatol 1997;26:574–583.
Alwayn IP, Verbesey JE, Kim S, Roy R, Arsenault DA, Greene AK, et al. A critical role for matrix metalloproteinases in liver regeneration. J Surg Res 2008;145:192–198.
Wang Y, Wei Y, Huang J, Li X, You D, Wang L, et al. Prognostic value of matrix metalloproteinase-2 protein and matrix metalloproteinase-9 protein in colorectal cancer: a meta-analysis. BMC Cancer 2024;24:1065.
Wolosowicz M, Prokopiuk S, Kaminski TW. The complex role of matrix metalloproteinase-2 (MMP-2) in health and disease. Int J Mol Sci 2024;25.
Scheuer PJ. Liver biopsy size matters in chronic hepatitis: bigger is better. Hepatology 2003;38:1356–1358.
Hammel P, Couvelard A, O'Toole D, Ratouis A, Sauvanet A, Fléjou JF, et al. Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct. N Engl J Med 2001;344:418–423.
Joseph J. Serum Marker panels for predicting liver fibrosis - an update. Clin Biochem Rev 2020;41:67–73.
Maroto-García J, Moreno Álvarez A, Sanz de Pedro MP, Buño-Soto A, González Á. Serum biomarkers for liver fibrosis assessment. Adv Lab Med 2024;5:115–130.
Guo R, Shi X, Wei X, Wei S. Analyzing the correlation between serum biomarkers and child-pugh score in liver cirrhosis. Altern Ther Health Med 2024;30:437–441.
Shah AG, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009;7:1104–1112.
De Matteis C, Cariello M, Graziano G, Battaglia S, Suppressa P, Piazzolla G, et al. AST to Platelet Ratio Index (APRI) is an easy-to-use predictor score for cardiovascular risk in metabolic subjects. Sci Rep 2021;11:14834.
Rungta S, Kumari S, Deep A, Verma K, Swaroop S. APRI and FIB-4 performance to assess liver fibrosis against predefined Fibroscan values in chronic hepatitis C virus infection. J Family Med Prim Care 2021;10:4082–4088.
Chowdhury AB, Mehta KJ. Liver biopsy for assessment of chronic liver diseases: a synopsis. Clin Exp Med 2023;23:273–285.
El-Kamary SS, Mohamed MM, El-Raziky M, Shardell MD, Shaker OG, ElAkel WA, et al. Liver fibrosis staging through a stepwise analysis of non-invasive markers (FibroSteps) in patients with chronic hepatitis C infection. Liver Int 2013;33:982–990.
Cheong JY, Um SH, Seo YS, Kim DJ, Hwang SG, Lee YJ, et al. Non-invasive index for predicting significant liver fibrosis: comparison of diagnostic performances in patients with chronic hepatitis B and C. Dig Dis Sci 2011;56:555–563.
Shan L, Wang F, Zhai D, Meng X, Liu J, Lv X. Matrix metalloproteinases induce extracellular matrix degradation through various pathways to alleviate hepatic fibrosis. Biomed Pharmacother 2023;161:114472.
Arthur MJP. Fibrogenesis II. Metalloproteinases and their inhibitors in liver fibrosis. Am J Physiol Gastrointest Liver Physiol 2000;279:G245-9.
Geervliet E, Moreno S, Baiamonte L, Booijink R, Boye S, Wang P, et al. Matrix metalloproteinase-1 decorated polymersomes, a surface-active extracellular matrix therapeutic, potentiates collagen degradation and attenuates early liver fibrosis. J Control Release 2021;332:594–607.
Mahmoud AA, Bakir AS, Shabana SS. Serum TGF-β, Serum MMP-1, and HOMA-IR as non-invasive predictors of fibrosis in Egyptian patients with NAFLD. Saudi J Gastroenterol 2012;18:327–333.
Lichtinghagen R, Huegel O, Seifert T, Haberkorn CI, Michels D, Flemming P, et al. Expression of matrix metalloproteinase-2 and -9 and their inhibitors in peripheral blood cells of patients with chronic hepatitis C. Clin Chem 2000;46:183–192.
Takahara T, Furui K, Yata Y, Jin B, Zhang LP, Nambu S, et al. Dual expression of matrix metalloproteinase-2 and membrane-type 1-matrix metalloproteinase in fibrotic human livers. Hepatology 1997;26:1521–1529.
Xie H, Su D, Zhang J, Ji D, Mao J, Hao M, et al. Raw and vinegar processed Curcuma wenyujin regulates hepatic fibrosis via bloking TGF-β/Smad signaling pathways and up-regulation of MMP-2/TIMP-1 ratio. J Ethnopharmacol 2020;246:111768.
Murawaki Y, Yamada S, Ikuta Y, Kawasaki H. Clinical usefulness of serum matrix metalloproteinase-2 concentration in patients with chronic viral liver disease. J Hepatol 1999;30:1090–1098.
Prystupa A, Boguszewska-Czubara A, Bojarska-Junak A, Toruń-Jurkowska A, Roliński J, Załuska W. Activity of MMP-2, MMP-8 and MMP-9 in serum as a marker of progression of alcoholic liver disease in people from Lublin Region, eastern Poland. Ann Agric Environ Med 2015;22:325–328.
Toyoda H, Kumada T, Kiriyama S, Tanikawa M, Hisanaga Y, Kanamori A, et al. Higher hepatic gene expression and serum levels of matrix metalloproteinase-2 are associated with steatohepatitis in non-alcoholic fatty liver diseases. Biomarkers 2013;18:82–87.
Macías J, Mira J, Gilabert I, Neukam K, Roldán C, Viloria M, et al. Combined use of aspartate aminotransferase, platelet count and matrix metalloproteinase 2 measurements to predict liver fibrosis in HIV/hepatitis C virus-coinfected patients. HIV Med 2011;12:14–21.
Boeker KH, Haberkorn CI, Michels D, Flemming P, Manns MP, Lichtinghagen R. Diagnostic potential of circulating TIMP-1 and MMP-2 as markers of liver fibrosis in patients with chronic hepatitis C. Clin Chim Acta 2002;316:71–81.
Larrousse M, Laguno M, Segarra M, De Lazzari E, Martinez E, Blanco JL, et al. Noninvasive diagnosis of hepatic fibrosis in HIV/HCV-coinfected patients. J Acquir Immune Defic Syndr 2007;46:304–311.
Reif S, Somech R, Brazovski E, Reich R, Belson A, Konikoff FM, et al. Matrix metalloproteinases 2 and 9 are markers of inflammation but not of the degree of fibrosis in chronic hepatitis C. Digestion 2005;71:124–130.
Leroy V. Other non-invasive markers of liver fibrosis. Gastroenterol Clin Biol 2008;32:52–57.
Walsh KM, Timms P, Campbell S, MacSween RN, Morris AJ. Plasma levels of matrix metalloproteinase-2 (MMP-2) and tissue inhibitors of metalloproteinases -1 and -2 (TIMP-1 and TIMP-2) as noninvasive markers of liver disease in chronic hepatitis C: comparison using ROC analysis. Dig Dis Sci 1999;44:624–630.
Roy R, Yang J, Moses MA. Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clin Oncol 2009;27:5287–5297.
Riazi K, Swain MG, Congly SE, Kaplan GG, Shaheen AA. Race and ethnicity in non-alcoholic fatty liver disease (NAFLD): a narrative review. Nutrients 2022;14:4556.
- Abstract Viewed: 275 times
- PDF Downloaded: 117 times